Pancreas Cancer Clinical Trials

36 studies are recruiting for pancreas cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer

   Background: - Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors. This study will collect such samples from people already scheduled to hav…

   Stage

   Not phased

   Ages

   2 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT01915225 on ClinicalTrials.gov

2. Pancreatic Cancer Early Detection Consortium

   The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   Honor Health Research Institute, Scottsdale, Arizona

   Locations

   62 in total

   Run by

   Arbor Research Collaborative for Health

   See if you can join NCT04970056 on ClinicalTrials.gov

3. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalatio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Angeles Clinic and Research Institute, Los Angeles, California

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

4. ctDNA Assay in Patients With Resectable Pancreatic Cancer

   The purpose of this study is to determine the proportion of positive ctDNA -freely circulating tumor DNA fragments found in the blood plasma- in patients with pancreatic cancer and to better understand the relationship between possible ctDNA biomarkers and patient survival. A successful study may p…

   Stage

   Not phased

   Ages

   18 to 99

   Site

   University of Oklahoma, Oklahoma City, Oklahoma

   Locations

   2 in total

   Run by

   University of Oklahoma

   See if you can join NCT05052671 on ClinicalTrials.gov

5. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

   Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Banner Health, Gilbert, Arizona

   Locations

   16 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT04981119 on ClinicalTrials.gov

6. The Cancer of the Pancreas Screening-5 CAPS5)Study

   Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Yale University, New Haven, Connecticut

   Locations

   9 in total

   Run by

   Johns Hopkins University

   See if you can join NCT02000089 on ClinicalTrials.gov

7. T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer

   This phase I trial studies the side effects and best dose of autologous CD8+ and CD4+ transgenic T cells expressing high affinity KRASG12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) and to see how well they work in treating patients with solid tumor cancers that has spread from where i…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   Fred Hutchinson Cancer Center

   See if you can join NCT06043713 on ClinicalTrials.gov

8. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

   Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Southern California, Los Angeles, California

   Locations

   11 in total

   Run by

   Nammi Therapeutics Inc

   See if you can join NCT06582017 on ClinicalTrials.gov

9. INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study

   The purpose of the study is to characterize baseline multidisciplinary tumor board (MDTB) context and variability, evaluate the relationship between baseline fitness of patients with cancer and initial treatment recommendations, and assess the impact of the INSPIRE intervention, which involves incl…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   3 in total

   Run by

   University of Alabama at Birmingham

   See if you can join NCT07671937 on ClinicalTrials.gov

10. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

    The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moores Cancer Center UC San Diego Health, La Jolla, California

    Locations

    21 in total

    Run by

    Bicara Therapeutics

    See if you can join NCT04429542 on ClinicalTrials.gov

11. Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

    The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Cooper Hospital University Medical Center, Camden, New Jersey

    Locations

    4 in total

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT06593431 on ClinicalTrials.gov

12. Promoting CT Engagement for Pancreatic Cancer With App

    To develop a culturally tailored informational mobile application and test whether it will increase participation among Black pancreatic cancer subjects in clinical trial discussions with their care team. This project aims to identify and address barriers to enrollment of Black subjects in pancreat…

    Stage

    Not phased

    Ages

    18 and older

    Site

    UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

    Locations

    2 in total

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06252545 on ClinicalTrials.gov

13. EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

    This research study is being conducted to improve the quality of care of participants who have a diagnosis of gastrointestinal cancer (anal, colon, rectal, esophageal, stomach, small bowel, appendix, pancreas, gall bladder, liver, neuroendocrine tumor of gastrointestinal origin). This study has 3 c…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio

    Run by

    Case Comprehensive Cancer Center

    See if you can join NCT06263088 on ClinicalTrials.gov

14. Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection

    The investigators hypothesize that abnormalities in thromboelastography (TEG) parameters in patients with liver, pancreas, biliary, esophageal, colorectal, and lung adenocarcinoma can serve as biomarkers for oncologic disease burden, cancer recurrence and overall survival as well as thrombotic and …

    Stage

    Not phased

    Ages

    18 to 99

    Site

    University of Colorado Denver, Aurora, Colorado

    Locations

    2 in total

    Run by

    University of Colorado, Denver

    See if you can join NCT05517811 on ClinicalTrials.gov

15. MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial

    This study is a dynamically adjustable prospective longitudinal study designed to capture biospecimen (biopsy, blood, surgical) and multimodal treatment-related data (imaging, dosimetry, clinical) before, during, and after treatment with definitive-intent chemoradiotherapy for patients with locally…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT05975593 on ClinicalTrials.gov

16. Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients w…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Investigative Site #108, Goodyear, Arizona

    Locations

    18 in total

    Run by

    MOMA Therapeutics

    See if you can join NCT06545942 on ClinicalTrials.gov

17. Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

    This is a phase 2a, randomized, double-blinded, placebo-controlled pilot clinical trial determining the impact of riluzole therapy on circulating brain derived neuropathic factor (BDNF) levels in cancer survivors (recently completing prior treatment regimens) or patients who have received whole bra…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California

    Run by

    University of California, Irvine

    See if you can join NCT06580002 on ClinicalTrials.gov

18. A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening

    The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07612046 on ClinicalTrials.gov

19. Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy

    For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois

    Locations

    3 in total

    Run by

    Northwestern University

    See if you can join NCT04616131 on ClinicalTrials.gov

20. Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

    The purpose of this study is to understand the safety and estimate the efficacy of combining anti-cluster of differentiation 3 (CD3) x anti-Epidermal Growth Factor Receptor (EGFR) bispecific antibody fresh peripheral blood mononuclear cells (EGFR FPBMC) for patients with metastatic or unresectable …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Virginia, Charlottesville, Virginia

    Run by

    University of Virginia

    See if you can join NCT06479239 on ClinicalTrials.gov

21. A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

    The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesotheli…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Banner Health, Gilbert, Arizona

    Locations

    12 in total

    Run by

    A2 Biotherapeutics Inc.

    See if you can join NCT06051695 on ClinicalTrials.gov

22. Autologous CAR-T Cells Targeting B7-H3 in PDAC

    The purpose of this gene therapy research study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9.CAR.B7-H3 T cells) in patients with pancreatic ductal adenocarcinoma that came back after rec…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06158139 on ClinicalTrials.gov

23. Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence

    This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence post-surgery.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin

    Run by

    Medical College of Wisconsin

    See if you can join NCT06228599 on ClinicalTrials.gov

24. Axelopran for Advanced Cancer in Patients Receiving Opioids

    The primary objective of this single arm, open label, phase II trial is to determine if axelopran use impacts cancer control in patients with advanced cancers of the lung, breast, pancreas, and prostate. The primary study period for assessing the primary aim is through day 43 (6 weeks). The main qu…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    HealthPartners Frauenshuh Cancer Research Center, Saint Louis Park, Minnesota

    Locations

    2 in total

    Run by

    HealthPartners Institute

    See if you can join NCT07354919 on ClinicalTrials.gov

25. Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

    Advanced pancreatic cancer patients receiving treatment of adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant defactinib plus avutometinib will have increased progression-free survival (PFS) compared to historical PFS rates for patients receiving adaptive SBRT alone.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT07126158 on ClinicalTrials.gov